Podcasts about rectal cancer

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Hi everyone, I have Kate Baldry joining me today to share her insights into early onset colo-rectal cancer, a diagnosis that is happening more and more. As a Research and Development Underwriter at Hannover Re, Kate has incredible access and insight to claims and health data. Kate has been spending time analysing the increasing rate of bowel cancer diagnoses and any trends that could be causing this.It was particularly interesting for me as Kate shares that some of the patterns that they have seen are due to people being tall, healthy BMI and having their gallbladder removed - I hit all three of these! The main takeaway that I have from our chat is that whilst these factors might contribute to bowel cancer diagnosis, at the moment it is still very much an unknown. There are a lot of theories but no definitive reason as to why bowel cancer diagnoses are increasing.The key takeaways:Early onset bowel cancer is when there is a diagnosis before the age of 50Deep dives into claims have shown that many claimants had no family history of bowel cancer or other disclosures related to digestive health The TNM score of the bowel cancer diagnosis is essential in determining what the options for protection insurance will beNext time I will be joined by Phil Jeynes, who will be sharing with us his story of a bowel cancer diagnosis and what life has been like for him since. Remember, if you are listening to this as part of your work, you can claim a CPD certificate on our website, thanks to our sponsors NextGen Planners.

How to perform endoscopic intermuscular dissection in early rectal cancer - learn from the best: Barbara Bastiaansen

Endoscopic intermuscular dissection has revolutionized early rectal cancer therapy. Barbara Bastiaansen guides us through preparation, indications, and everything we need to know.

Join Dr. Refky Nicola and guest, Dr. Stephanie Nougaret, as they explore the evolution of MRI in rectal cancer staging, from the DISTANCE framework to the updated DISTANCED approach. Learn how advancements in imaging and structured reporting are shaping patient management and treatment planning. MRI of the Rectum: A Decade into DISTANCE, Moving to DISTANCED. Nougaret et al. Radiology 2025; 314(1):e232838.

In this episode of the PRO podcast, join host Michael Buckstein, MD, PhD, as he sits down with Jennifer Wo, MD and Ann Raldow, MD, MPH to discuss the latest updates to the ASTRO Rectal Cancer Guidelines. In this episode, they break down key recommendations, the evolving role of radiation in rectal cancer management, and how these guidelines impact clinical decision-making. Tune in for expert insights on the latest evidence, practical applications, and what these updates mean for patient care.

In this JCO Article Insights episode, Peter Li summarizes “Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years,” by Dr. Jianwei Zhang et al. published on December 13, 2024. TRANSCRIPT Peter Li: Hello and welcome to the JCO Article Insights. I'm your host Peter Li and today we will be discussing the Journal of Clinical Oncology article, “Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years,” by Dr. Jianwei Zhang et al.  For a reminder to the audience, the FOWARC study is a Chinese-based study that looked into the treatment of locally advanced rectal cancers with neoadjuvant chemotherapy based regimens with or without radiation. This study was first published back in 2019 where the three-year data showed no difference in three-year disease-free survival over survival between the three study arms. As a reminder of what those arms were, there were one historical control and two interventional arms. The control arm used 5-FU with radiation therapy with five cycles of 5-fluorouracil with radiation during cycles two to four followed by surgery and then seven cycles adjuvantly. Their first interventional arm was the same as the control arm with the addition of oxaliplatin on day 1of each cycle. And lastly, the third arm was FOLFOX only for four to six cycles followed by surgery and then six to eight cycles adjuvantly completing about a total of 12 weeks of chemotherapy.  They recruited about 495 patients with 165 patients randomized to each arm. They were relatively well balanced by age, clinical staging and distance from the anal verge. Median age was about mid-50s with a slight male predominance and patients were primarily stage 3 with 20% to 30% being stage 2. About 30% had clinical T4 disease and about 25% had clinical N2 disease. Median follow up time was 122.5 months or 10 years and their follow up endpoints were disease-free survival, overall survival and local recurrence, and they also performed subgroup analyses based on post surgical pathological staging. Survival was analyzed using Kaplan-Meier method with a significant threshold of p being less than 0.05. About 451 patients actually underwent surgery, which is about 91% of patients. The main reason for not going through surgery was due to refusal but one was due to toxicity and two were due to disease progression in the control arm. Follow up loss rate was about 10% in each group. Now looking at their primary endpoints in their initial study, local recurrence was about 8.8% in the control arm versus 7.9% in the FOLFOX radiation group versus 9.2% in the FOLFOX only group. Distant metastasis was about 30% in each arm and the sites of metastases were primarily in the lung and liver.   Now, following up with 10 years, there were only three new events in the chemoradiation group with local recurrence happening at 10.8% in the control arm versus 8% in the FOLFOX RT group versus 9.6% in the chemo only group. These findings were not statistically significant. In their subgroup analysis by pathological staging, they found that pathological CR or complete response had a lower rate of local recurrence compared to those with increasing pathological staging coming in at 3% versus 4.3% versus 11.6% versus 15.8% in pCR versus Stage 1, 2, 3 respectively. And they found no difference in each stage with each interventional arm. Looking at long term survival their 10-year disease free survival showed 52.5% in the 5-FU radiation group versus 62.6% in the FOLFOX RT group versus 60.5% in the chemotherapy only group with no statistically significant difference between three groups. By pathological staging, they found improved 10-year disease survival in those who achieved pathological complete response versus those who did not with 84.3% in the pCR group versus 78.7% versus 56.8% versus 27.7% in the stage 1 versus 2 versus 3 group. And again they found no statistical significance difference between each arm.   Now looking at the 10-year overall survival rates between the three arms, in the control arm the 10-year overall survival was 65.9% versus 72.3% in the FOLFOX RT group versus 73.4% in the chemo only group. By pathological stage, again, they showed a statistically significant difference in those who achieved pCR versus those who had pathological stage 1 to 3 disease with overall survival being 92.4% in those who achieved pCR versus 84.9% versus 68.6% versus 48.8% in stage 1, 2, 3 respectively. Now in the discussion, authors mentioned that with a median follow up of 10 years, FOLFOX alone had similar disease-free survival, local recurrence and distant metastasis and overall survival compared to those who received neoadjuvant chemoradiation, justifying the omission of radiation without compromising results or outcomes for each patient. There were no differences in subgroup analysis for disease free survival local recurrence or overall survival based on pathological staging. There were only three new events compared to the last follow up, with local recurrence happening only in the chemo radiation groups. Local recurrence rates at 10 years was about 10%. Compared to other clinical trials such as CAO, ARO or AIO-94, the rate of local recurrence was similar to those historical trials.  The authors also compared their findings to the PROSPECT study which looks at the use of total neoadjuvant chemo radiation versus chemotherapy alone, which boasted only about a 2% local recurrence rate. But as a reminder, high risk locally advanced rectal cancers were excluded, mainly those with T4 or N2 disease, which may explain the difference in terms of local recurrence in the PROSPECT versus this study. Another finding is that pathological complete responses are also an important prognostic marker with lower 10-year local recurrence rate, disease-free survival and overall survival with worse outcomes with increased pathological staging. Distant metastasis rates were still at 30%, with the most common site being lung then liver then lymph nodes consistent with other historical studies. Chemotherapy seemed to be better at reducing liver mets than lung metastasis per their findings. In their post hoc analysis of their own study, chemo radiation was also associated with higher incidence of low anterior resection syndrome and persistent ostomy compared to chemotherapy alone, meaning that they had better quality of life with the chemotherapy only approach.  In conclusion, a chemotherapy only approach can be safe and a feasible treatment for locally advanced rectal cancer without compromising outcomes. Omission of radiation may reduce the risk of overtreatment and improve quality of life for some of these patients. However, this does not necessarily exclude the role of radiation as it may still play a role in a response escalation approach for those who do not respond to chemotherapy alone.   This wraps up today's episode. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Christopher C. Muth, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from January 18-24, 2025.

Among patients with colorectal cancer and synchronous liver metastases, the subgroup with a primary cancer in the rectum is especially challenging. Compared with colon cancer, most patients with stage IV rectal cancer will have locally advanced primary tumors at increased risk for obstructive and/or post-operative complications resulting in delays in systemic therapy. In this episode from the HPB team at Behind the Knife, listen in on the discussion about treatment sequencing for synchronous liver metastasis from rectal cancer Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center. Learning Objectives ·      Develop an understanding of the three treatment sequences for resection of disease in patients with synchronous liver metastasis from a primary rectal cancer (reverse, combined, and classic approach) ·      Develop an understanding of the benefits, risks, and nuances of each of the three treatment sequences ·      Develop an understanding of which patient cases each treatment sequence is ideal for as well as which cases they are not suitable for. Papers Referenced (in the order they were mentioned in the episode): 1)    Conrad C, Vauthey JN, Masayuki O, et al. Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. Ann Surg Oncol. 2017 Dec;24(13):3857-3864.  https://pubmed.ncbi.nlm.nih.gov/28929463/ 2)    Maki H, Ayabe RI, Nishioka Y, et al. Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer. Ann Surg Oncol. 2023 Sep;30(9):5390-5400. doi: 10.1245/s10434-023-13656-4. Epub 2023 Jun 7. Erratum in: Ann Surg Oncol. 2023 Sep;30(9):5405. https://pubmed.ncbi.nlm.nih.gov/37285096/ Additional Suggested Reading Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006 Jul;93(7):872-8.  https://pubmed.ncbi.nlm.nih.gov/16671066/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Welcome back to The Genetics Podcast! Today, we're joined by Dr. Luis Diaz, Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering and a White House Appointee to the National Cancer Advisory Board. Dr. Diaz's career has been defined by his commitment to translating cutting-edge cancer genomics into clinical practice. In this episode, he and Patrick dive into his groundbreaking trial on mismatch repair (MMR)-deficient rectal cancer, along with his pioneering work on liquid biopsies, immunotherapies targeting tumors with microsatellite instability, and advancements in precision oncology. To learn more about Dr. Diaz and his work, visit his research page here: https://www.mskcc.org/research-areas/labs/luis-diaz.

In this episode of the Evolving Wellness Podcast, we're joined by Dr. Roger Seheult, an ICU physician, pulmonologist, and sleep expert, who's also the founder of the wildly popular YouTube channel MedCram. Dr. Seheult reveals the surprising connection between light exposure and health, discussing how hospital lighting environments are contributing to illness and the critical role of circadian rhythms in healing. He shares fascinating insights from his research and practical advice on improving circadian health, including the benefits of infrared light, forest bathing, and aligning with natural sunlight. From shift work impacts to the science of daylight savings and even melatonin myths, this episode is packed with valuable tips and eye-opening information for optimizing your health through better light management. Sponsored By:  Black Lotus Shilajit Visit: ⁠www.blacklotusshilajit.com⁠ and Use Code: SARAHK for 15% the entire site! Upgraded Formulas: Use code: YOGI for 10% off at ⁠www.upgradedformulas.com⁠ Viva Rays Go to ⁠vivarays.com⁠ & use code: YOGI to save 15% Timestamps:  00:00:00 - Introduction  00:03:31 - The MedCram YouTube Channel  00:04:47 - Discovering Circadian Biology   00:08:59 - The Benefits of Infrared Light   00:11:26 - Why You Can't Biohack Light   00:13:08 - Case Study: Light's Role in COVID-19   00:15:30 - The Healing Power of Nature 00:19:41 - The Science of Circadian Rhythms & Light Exposure at Night   00:24:02 - Hormonal Health & Cancer Rates 00:26:04 - Shift Work and Night Shifts 00:28:43 - How Daylight Savings Affects Flu Spikes   00:30:27 - Harvard Kennedy School Study: Sunlight & Flu Prevention   00:33:38 - The Dangers of Over-Supplementation   00:36:19 - Practical Tips for Night Shift Workers   00:38:53 - Ketosis, Intermittent Fasting, and Circadian Health   00:39:43 - The Link Between Eating at Night and Rectal Cancer   00:45:45 - Breakfast vs. Dinner: Timing and Health Benefits   00:48:08 - Medication Timing and Its Impact on Circadian Rhythms   00:50:15 - Training Your Circadian System for Optimal Health   00:51:03 - Why We Crave Snacks at Night   00:55:33 - Changing the Medical System 01:03:33 - UV Light and the Risk of Skin Cancer   01:07:44 - The Truth About Melatonin Supplementation   Check Out Dr. Roger: Website  Youtube X (Twitter) Instagram This video is not medical advice & as a supporter to you and your health journey - I encourage you to monitor your labs and work with a professional! ________________________________________ Get all my free guides and product recommendations to get started on your journey! https://www.sarahkleinerwellness.com/all-free-resources Check out all my courses to understand how to improve your mitochondrial health & experience long lasting health! (Use code PODCAST to save 10%) -  https://www.sarahkleinerwellness.com/courses Sign up for my newsletter to get special offers in the future! -https://www.sarahkleinerwellness.com/contact Free Guide to Building your perfect quantum day (start here) - https://www.sarahkleinerwellness.com/opt-in-9d5f6918-77a8-40d7-bedf-93ca2ec8387f My free product guide with all product recommendations and discount codes: https://www.sarahkleinerwellness.com/resource_redirect/downloads/file-uploads/sites/2147573344/themes/2150788813/downloads/84c82fa-f201-42eb-5466-0524b41f6b18_2024_SKW_Affiliate_Guide_1_.pdf My Circadian App - Apple My Circadian App - Android My Circadian App - Youtube

In this episode of SurgOnc Today®, Prakash Pandalai, MD, Georgios Karagkounis, MD, and Fadwa Ali, MD, review the evolution of the Watch and Wait strategies in the management of rectal cancer patients with an emphasis on challenges, current clinical trials, and future directions.

Newfoundland and Labrador leads the country in colo-rectal cancer rates, and people are also being diagnosed younger. It used to be that you'd start talking to your doctor once you reached the age of 50, but some experts are saying that uncomfortable conversation should be happening a decade or more earlier. Dr. Jerry McGrath is a gastroenterologist and the Medical Director of the Newfoundland and Labrador Colon Cancer Screening Program.

Deputy Editor Salma Jabbour hosts Dr. Christopher Anker, Professor of Radiation Oncology and Program Co-Leader in the Cancer Host and Environment program at the University of Vermont Cancer Center, and Dr. Leila Tchelebi, Associate Professor of Radiation Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, respectively the first and second authors of a guideline published in this issue, Executive Summary of the American Radium Society Appropriate Use Criteria for Non-Operative Management for Rectal Adenocarcinoma: Systematic Review and Guidelines

MSI-high/MMRd rectal cancer treatment guidelines are being re-written. A brief synopsis of why treatment guidelines are changing so quickly in this space. Also, listeners helped out in explaining the ribociclib storage & stability change. Hint: https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2

Send us a textCurious about the latest breakthroughs in oncology treatment? Prepare to have your perspective shifted and hopefully a few laughs too, as we dissect the most compelling research and clinical insights with our expert hosts, Professor Craig Underhill, Dr. Kate Clarke, and Professor Christopher 'CJ' Jackson. Today's episode covers an eclectic mix of papers. Craig tackles patient-reported outcomes. Kate looks at oral cannabis for nausea and vomiting. And CJ reviews the ASCO Guidelines for the management of locally advanced rectal cancer.  Plus each Host presents their favourite Quick Bite papers. For papers, bios and other links visit the Show Notes on our website.For the latest oncology news visit www.oncologynews.com.au.We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

•Guess The (Commenter's) Race •Carefully Skimming 11,000 Cases Of Chicken Wings •Popeye's Be Outta Chicken •Evicted Store = Free Shit (For Blacks) •Black People Make Great Content •Tone's Read Ever Shampoo Bottle There Was •Tripping Over Heads In Mexican Parking Lots •825 Pound Walki… Laying Down Fire Hazard •Roaring Turbo Rectal Cancer •Italian Man Wins Covid Monkey AIDS Pox •Caller Confirms This Was A Decent Episode •Sword In Hand VS Sword In Pants ⚔️  …And MUCH More!!   Support Us on Patreon Become a Dougalo and get weekly bonus episodes and ad free public episodes by joining our Patreon.   Join us at http://patreon.com/whosright For superchat sounds, send them over to Doug at doug.whosrightpodcast@gmail.com with "superchat" in the subject line. Got burning questions for Dear Flabby? Submit them for our next episode! Head to www.whosrightpodcast.com and click on the "Dear Flabby" link to share your queries. We're eager to hear from you! Love our intro song? Check out Masticate on Spotify: https://tinyurl.com/52psn3dk (Original Who's Right Theme Song by Peter Noreika: https://open.spotify.com/artist/3wYqlhflN3lNA5N5BUgeeR) This episode is sponsored by Arizona Bay Candy Co. Indulge your sweet tooth with Arizona Bay Candy Co.'s range of freeze-dried candies. Treat yourself to something special at http://www.arizonabaycandy.com Stay Connected! Don't miss any updates or content. Find all our social media links conveniently located in our Linktree: http://linktr.ee/whosrightpodcast Follow Us: Twitter: @whosrightpodcast Instagram: @whosrightpodcast Facebook: Who's Right Podcast

In this episode, Tom Varghese, MD, FACS is joined by Calista M Harbaugh, MD, MSc, from the University of Michigan. They discuss Dr Harbaugh's recent study, “Association of National Accreditation Program for Rectal Cancer Accreditation with Outcomes after Rectal Cancer Surgery,” in which the authors found that hospitals accredited by the National Accreditation Program for Rectal Cancer are associated with lower short- and long-term morbidity and mortality, but few programs achieve accreditation status.   Disclosure Information: Drs Varghese and Harbaugh have nothing to disclose.   To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date.   Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.   #JACSOperativeWord

  Dr. Meyerhardt is the Chief Clinical Officer for Dana-Farber and Co-Director of the Colon and Rectal Cancer Center as a medical oncologist specializing in cancers in the GI tract. He is also the Douglas Gray Woodruff Chair in Colorectal Cancer Research and a Professor of Medicine at Harvard Medical School.       Dr. Meyerhardt received his MD from Yale School of Medicine in 1997. He completed a residency in internal medicine at Beth Israel Deaconess Medical Center, in Boston, followed by a medical oncology fellowship at DFCI. He joined the Gastrointestinal Cancer Center at Dana-Farber in 2002.

Dr. Sepideh Gholami and Dr. Aaron Scott join us to discuss the latest evidence-based guideline from ASCO on the management of locally advanced rectal cancer. They review the recommendation highlights on topics including assessment, total neoadjuvant therapy, timing of chemotherapy, nonoperative management, and immunotherapy. Additionally, we discuss the importance of this guideline for both clinicians and patients, and the outstanding research questions in the management of locally advanced rectal cancer. Read the full guideline, “Management of Locally Advanced Rectail Cancer: ASCO Guideline” at www.asco.org/gastrointestinal-cancer-guidelines. TRANSCRIPT  This guideline, clinical tools, and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.24.01160    Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at ASCO.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Aaron Scott from the University of Arizona Cancer Center and Dr. Sepideh Gholami from Northwell Health, co-chairs on, “Management of Locally Advanced Rectal Cancer: ASCO Guideline.” Thank you for being here, Dr. Scott and Dr. Gholami. Dr. Sepideh Gholami: Thank you for having us. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Scott and Dr. Gholami, who have joined us here today, are available online with a publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to kick us off on the content of this episode, Dr. Gholami, first, what is the purpose and scope of this guideline on locally advanced rectal cancer? Dr. Sepideh Gholami: Well, I think, historically, this is the group of patients with locally advanced rectal cancer for which we've used multiple therapies to address their management. And with the advent of the total neoadjuvant approach, we really have seen tremendous changes. So the purpose really of these guidelines was to consolidate the various approaches that we've had in several clinical trials and to provide the oncology community a general management recommendation guideline to really optimize the outcomes for these patients. And I would further notice that with the specifics to like which patients are included for these, so we define patients with locally advanced rectal cancer as any of those patients with T3 or T4 tumors and/or lymph node positive disease. Brittany Harvey: Great. I appreciate you providing that background and context of this guideline. So then, next, I'd like to review the key recommendations of this guideline. So, Dr. Scott, starting with the first section of the guideline, what are the recommendations for assessment of locally advanced rectal cancer? Dr. Aaron Scott: Yeah, thank you. So really, we were charged with trying to answer, I think, several very important questions as it comes to the treatment of locally advanced rectal cancer. And the first step in doing so is to define the patient group. So, as far as the first section goes in the assessment, we were really charged with defining what locally advanced rectal cancer means. We think that this is best done with a high resolution pelvic MRI, dedicated rectal sequence prior to any treatment for risk assessment and proper staging, and the use of standardized synaptic MRI is recommended that includes relation of the primary tumor to the anal verge, sphincter complex, pelvic lymph nodes, the mesorectal fascia, otherwise known as the MRF, and includes assessment of the EMVI tumor deposits and lymph nodes. Brittany Harvey: I appreciate you reviewing those highlights for assessment of locally advanced rectal cancer. So following that, Dr. Gholami, what does the panel recommend regarding total neoadjuvant therapy and standard neoadjuvant chemotherapy for patients with proficient mismatch repair or microsatellite stable tumors? Dr. Sepideh Gholami: Yeah, thanks so much for that question, Brittany. I would say that the guidelines really provide a lot more details, but in general, the consensus was that TNT should be offered as really initial treatment for patients with low rectal locally advanced rectal cancers or those who have higher risk for local and distant metastases. Those risk factors included anyone with either T4 disease, extramural vascular invasion and/or tumor deposits identified on the MRI for any threatening of the mesorectal fascia or the intersphincteric plane. Brittany Harvey: Excellent. So then, Dr. Gholami just discussed who should be offered TNT. But Dr. Scott, what are the recommendations regarding timing of TNT? Dr. Aaron Scott: So the way I take this question, think about this question, is a lot of the work that we put toward defining whether chemoradiation plus consolidation versus induction chemotherapy is the right choice, and there are a lot of implications to consider in this situation. The panel recognizes that the decision to proceed with chemoradiation followed by chemo versus chemotherapy followed by chemoradiation often depends on logistics regarding the time to treatment start, concern for distant metastases, and desire for local control that may impact surgical decision making. When we look at the subgroup analysis for overall survival of patients treated with TNT, it doesn't seem to matter which approach you take. Either induction or consolidation doesn't seem to have an impact on overall survival. However, there are other outcomes that may be of importance. Based on the CAO/ARO/AIO-12 randomized phase II trial, both pathologic complete response rates and sphincter sparing surgery were numerically higher with consolidation chemo. That said, there was no difference in disease free survival. So if you have a patient that really wants to consider some sort of sphincter sparing surgery, or a patient has a highly symptomatic disease burden, etc., these are patients that we would recommend starting with chemoradiation followed by consolidation chemotherapy. Brittany Harvey: Understood. And so you have both mentioned radiation included in treatment regimens. So Dr. Gholami, what is recommended in the neoadjuvant setting? Short course radiation or long course chemoradiation? Dr. Sepideh Gholami: Yeah, we actually had a really long discussion about this, but I think in general the consensus was that if radiation is included in any patient's treatment plan, neoadjuvant long course chemoradiation is preferred over short course RT for patients with locally advanced rectal cancer. And really the recommendation was based on the long term results that we've seen from the RAPIDO phase 3 clinical trial, which showed a significant higher rate of five year local regional failure with a total neoadjuvant approach with short course of 10% compared to the standard chemo RT with only 6% of the local recurrence rate. So that's why they opted for the long course, if the patients can actually tolerate it. Brittany Harvey: Excellent. I appreciate reviewing the recommendation and the supporting evidence that the panel reviewed to come to those recommendations. Then following that, Dr. Scott, for those patients who have a complete clinical response after initial therapy, what is recommended regarding nonoperative management? Dr. Aaron Scott: First, I would like to just say that this is really an area that still remains somewhat controversial and needs more investigation to best select patients for this approach. This topic was not systematically reviewed for the ASCO guideline. However, the expert panel was surveyed and most agreed with the time interval used in the OPRA phase 2 trial, which assessed patients for clinical complete response within eight weeks plus or minus four weeks after completion of TNT. Expert panel members and reviewers noted that if the radiation therapy component of TNT is delivered first, then an eight week interval following subsequent chemotherapy may result in a prolonged period of no treatment and therefore a first assessment of this response in this scenario would occur on the earlier side of the recommended interval. If a near clinical complete response is noted, then reevaluation within eight weeks is recommended to assess for developing a clinical complete response. Brittany Harvey: Absolutely. That information is helpful to understand what is recommended regarding nonoperative management and clinical complete responses. Then the final clinical question, Dr. Gholami, for patients with tumors that are microsatellite instability high or mismatch repair deficient, which treatment strategy is recommended? Dr. Sepideh Gholami: Yeah, I think we really came up to summarize that in general, when there is no contraindication to immunotherapy, then patients with MSI high tumors should be really offered immunotherapy. The evidence for this recommendation was relatively low, though, just due to the small sample size of the data that's currently available. But we did want to highlight that the data is very promising, but a definitive recommendation by the committee should be validated in future larger clinical trials. Brittany Harvey: Absolutely. Well, thank you both for reviewing the highlights of these recommendations for each clinical question. Moving on, Dr. Scott, in your view, what is the importance of this guideline and how will it impact both clinicians and patients with locally advanced rectal cancer? Dr. Aaron Scott: This would be the first guideline through ASCO to spell out management options for locally advanced rectal cancer. This has largely been needed due to the increased number of phase II and III trials investigating the specific patient population that have investigated a variety of different TNT approaches and treatment combinations utilizing systemic therapy, radiation, and surgical treatment. So, in this guideline, we really set out to define what locally advanced rectal cancer is, have organized and analyzed impactful large randomized studies to address multimodality therapy, and have consolidated this information into what we consider a concise and generalizable approach to help clinicians and patients individualize their management based on specific clinical pathologic features of their cancer. Brittany Harvey: Yes, this has been a mountain of work to review all the evidence, consolidate it into a concise review of that evidence, and develop recommendations for best clinical practice for management of locally advanced rectal cancer. So then, finally, to wrap us up, Dr. Gholami, what are the outstanding questions regarding management of locally advanced rectal cancer? Dr. Sepideh Gholami: Yeah, I think I just want to reiterate, Brittany, what you mentioned, this was a tremendous amount of body work, and we really would like to thank the committee and everyone from ASCO to help us with creating these general guidelines. I think one of the outstanding questions really still remains is the use of circulating tumor DNA as a management tool for patients with rectal, locally advanced rectal cancer. And also, I think outside of what we can think of the straightforward populations to deduce from PROSPECT, be really interested to see what other patient populations, for example, could also potentially maybe avoid radiation therapy. And lastly, I think we really wanted to highlight that this guideline really focuses on the locally advanced, and it would be great to see future guidelines for early stage rectal cancer which will be forthcoming. Brittany Harvey: Definitely. We'll look forward to answering those outstanding questions and for upcoming guidelines on earlier stage rectal cancer. So, I want to thank you both so much for, as you said, the tremendous amount of work that went into these guidelines and thank you for taking the time to speak with me today, Dr. Scott and Dr. Gholami. Dr. Aaron Scott: Thank you. Dr. Sepideh Gholami: Thank you so much for having us. Appreciate it. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please read and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/CRC).

Rectal cancer is on the rise and it's high time we shine a light on it.  Because let's face it, our health — and even our bathroom habits, deserve our attention. Yes, we're talking about poop! But before you hit pause or start squirming in your seat, let me tell you why you need to stick around.  Joining us today is Marisa Peters, a true warrior who battled and survived rectal cancer. Not only is she a survivor, but she's also a passionate advocate of women's health. Motivated by her triumphant battle against late-stage cancer, Marisa founded Be Seen, a movement dedicated to emphasizing the significance of self-advocacy during pivotal moments in our lives. Marisa is a mother to three boys and previously had a career on Broadway as a vocalist.  Today, she's not here just to share her story but to shed light on this topic that's often shrouded in silence. We're delving into the signs and symptoms of rectal cancer, and all those little red flags that might be waving when your digestive system isn't quite on its A-game. And most importantly: regular screenings.  Get ready to laugh, learn, and maybe even cringe a little as we discuss all things related to rectal health. Trust me, you won't want to miss this! Visit whydidigetcancer.com for full show notes. --- This episode is sponsored in part by ButcherBox. I LOVE HIGH-QUALITY PROTEIN. I have a houseful at least once a week in the summer. I keep frozen protein ready for last-minute dinners. That's why I'm loving the offer from ButcherBox. They offer $30 off your first box and then FREE chicken thighs, salmon, or top sirloin FOR A YEAR IN EVERY BOX! Yup, you're getting paid to eat grass-fed and sustainable harvest protein.   ButcherBox: Meat Delivery Subscription   --- GUM Let's talk about a dental company that's making waves - GUM! First off, their Summit Toothbrush helps kick plaque to the curb.  And their unwaxed dental floss is PFAS-free! Why does that matter? PFAS are those pesky "forever chemicals" you don't want hanging out in your dental floss.  So, whether you're tackling plaque with their Summit toothbrush or keeping your floss game strong with their PFAS-free floss, GUM has you covered.  Find them at your nearest Costco, major retailers, or pharmacies, and let's keep those smiles shining bright! Happy brushing!   This podcast is for informational purposes only and none of the information should be construed as medical advice. Listeners should seek guidance from their own medical team before making any medical or lifestyle changes.

Marisa Peters is a rectal cancer survivor, women's health thought leader, and founder of BE SEEN. Marisa was diagnosed with Stage 3 rectal cancer in 2021 when she was 39 years old despite being an otherwise healthy and active mother of three young boys. She is on a mission to help other people take their colorectal health very seriously because it is, well, very serious. This conversation was so informative and, dare I say, even fun! The timing could not have been more perfect as we recorded this right before I was scheduled for my second colonoscopy as someone who has a family history of colon cancer. This gave Marisa and me much content for fodder!   Friends, listen to this episode, go sign the BE SEEN Pledge, and then get yourself scheduled for a colonoscopy. This is critical self-care.  Listen in to hear Marisa share: Symptoms of colon cancer to be looking for: blood loss through poop, increased urine urge, stomach pain, extreme fatigue  What you should be asking your doctor for if you have any concerns about color-tectal symptoms Her journey of being dismissed by doctors as she experienced symptoms over the course of 5.5 years before finally being diagnosed Your different options for your colonoscopy prep What to expect during your first colonoscopy How she talked to and continues to talk to her children about her cancer diagnosis and treatment What family support looked like and how they had to learn how to receive support as people who were used to being the givers of support in their community How to hold space for family and friends after they have gone through treatment - when they may be cancer free, but are still recovering physically and emotionally Why you and your family should take the BE SEEN Pledge to take steps toward maintaining colorectal health Links mentioned: Connect with Marisa and Be Seen: beseen.care Take the Be Seen Pledge: https://beseen.care/take-the-be-seen-pledge Marisa and Be Seen on IG Marisa and Be Seen on FB Marisa on LinkedIn Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain delve into the world of locally advanced rectal cancer, focusing on the latest treatment strategies and advancements in the field. Joined by esteemed guests Dr. Deborah Schrag, a medical oncologist from Memorial Sloan Kettering Cancer Center, and Dr. Krishan Jethwa, a radiation oncologist from the Mayo Clinic, the discussion centers around the groundbreaking Prospect study. This study challenges the traditional approach to rectal cancer treatment, emphasizing the importance of balancing therapeutic efficacy with minimizing chronic side effects. The conversation covers a range of topics, from the utilization of different chemotherapy regimens to the evolving paradigm of radiation therapy. Dr. Schrag and Dr. Jethwa provide valuable insights into determining the optimal treatment course for patients with locally advanced rectal cancer, including the selective omission of surgery and the significance of MSI high status in treatment decisions. Tune in to learn about the latest advancements in rectal cancer treatment, the implications of the Prospect study, and the importance of personalized, multidisciplinary approaches in oncology care. Don't miss out on this informative discussion that sheds light on the complexities of managing rectal cancer and the evolving treatment landscape. Stay informed and up-to-date with the Oncology Brothers podcast as they continue to explore the dynamic world of oncology treatment. Subscribe now and join the conversation! Guests: Dr. Deborah Schrag, Medical Oncologist, Memorial Sloan Kettering Cancer Center Dr. Krishan Jethwa, Radiation Oncologist, Mayo Clinic

Through elaborate multidisciplinary collaboration, institutions with National Accreditation Program for Rectal Cancer (NAPRC) standards can deliver a “high level of care” in the surgical treatment of patients with rectal cancer, according to Steven Wexner, MD, PhD, and Arielle Kanters, MD. In a conversation with CancerNetwork®, Wexner and Kanters detailed the history and advancement of the NAPRC as an interdisciplinary initiative to improve the outcomes of those undergoing surgery for rectal cancer. Wexner is the chair in the Department of Colorectal Surgery and director of the Ellen Leifer Shulman & Steven Shulman Digestive Disease Center at Cleveland Clinic, Florida, the founding chair of the NAPRC for the American College of Surgeons Commission on Cancer, and part of the executive committee of the Commission on Cancer. Kanters is a colorectal surgeon, associate fellowship program director, and surgeon leader of the NAPRC program at Cleveland Clinic Main Campus. Wexner spoke about the inspiration for developing the NAPRC as a mission to elevate the level of surgical outcomes in patients with rectal cancer across the United States to those he observed in European countries such as the United Kingdom and Scandinavia. He enlisted leaders from organizations including the Society of Surgical Oncology and the College of American Pathologists to outline and apply appropriate standards for surgical care in rectal cancer. Additionally, Kanters highlighted how enforcing precise guidelines and compliance measures through the NAPRC program facilitates multidisciplinary efforts with colleagues who specialize in radiology and pathology. She stated that these principles help individuals develop their skills across each department, thereby maintaining a high level of treatment for patients with rectal cancer.  Findings from a study published in the Journal of the American College of Surgeons indicated that mortality and complication rates appeared to be lower for patients who received surgery for rectal cancer at NAPRC-accredited institutions compared with those who were treated at non-accredited practices. Wexner and Kanters also discussed how potential advancements related to the use of neoadjuvant or adjuvant therapy may further improve patient outcomes in the field. Additionally, they spoke about updated research on immunotherapy and other modalities that they anticipate at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Reference Harbaugh CM, Kunnath NJ, Suwanabol PA, Dimick JB, Hendren SK, Ibrahim AM. Association of National Accreditation Program for Rectal Cancer Accreditation with outcomes after rectal cancer surgery. J Amer College Surg. Published March 28, 2024. doi:10.1097/XCS.0000000000001064

In this episode of SurgOnc Today, Alexander Parikh, MD, MPH, from the University of Texas – San Antonio and Chair of the SSO HPB disease site working group, and Laleh G. Melstrom, MD, MSCI, from City of Hope National Medical Center, are joined by Timothy Newhook, MD, from the University of Texas MD Anderson Cancer Center and Andreas Kaiser, MD, from the City of Hope. We will be discussing the management of synchronous rectal cancer with liver metastases.

For the first time in 100 episodes, we have a guest! In this week's episode, I'm joined by my good friend Jonathan Bradshaw to discuss his colorectal cancer journey, and the legal and social definitions of disability, with a little bit of nostalgia thrown in!Jonathan was diagnosed with Stage III Rectal Cancer in 2021 at age 40. His treatment included the removal of my colon and everything after, and he will poop in a bag for the rest of his life.  Despite being the largest cohort, Jonathan finds a lack of male representation in the Ostomate Community. He tries to be a voice and information source for men entering the poop-bag life.Jonathan's TEDx talk: Seat To Feet Investment PhilosophyJonathan's website: jpbradshaw.comJonathan's Instagram: @idbuyuamonkeySupport the showWatch my TEDx talk Email badattitudespod@gmail.comFollow @badattitudespod on Instagram, Facebook, Twitter, and ThreadsSupport the pod ko-fi.com/badattitudespodBe sure to leave a rating or review wherever you listen!FairyNerdy: https://linktr.ee/fairynerdy

Rick Greene, MD, discusses with Jean-Nicolas Vauthey, MD, a comparison of different surgical approaches to synchronous liver metastases from rectal cancer and their analysis of both clinicopathological and biological tumor factors associated with completion of the reverse approach. Professor Vauthey is the senior author of, “Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.” Dr. Vauthey is Professor of Surgery and Chief of the Hepato-Pancreato-Biliary Section, and the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX.

In this episode, Better Edge hosts a thought-provoking panel discussion with distinguished oncologists John Hayes, MD, Sheetal Kircher, MD, and renowned colorectal surgeon, Vitaliy Poylin, MD, on organ preservation approaches for rectal cancer. The conversation between these Northwestern Medicine experts delves into the evolution of treatment modalities, highlighting the shift from a one-size-fits-all approach to a more nuanced, patient-specific strategy. Their insights offer an insightful exploration of the balance between aggressive disease control and improved quality of life.

For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Pippa Hudson speaks to specialist surgeon Dr Maré du Plessis as we mark the start of Colo-rectal Cancer Awareness Month. For more podcasts go to www.primediaplus.com See omnystudio.com/listener for privacy information.

In celebration of the 125th Anniversary of ASCRS, our Then & Now series covers the struggles and triumphs of our specialty throughout history and to our present day as we look toward the future of colorectal surgery. In this episode, we're talking about rectal cancer with Dr. Julio Garcia-Aguilar.

The most important podcast you will hear this year. Ian Paquette speaks with Sean Langenfeld about nuances in Rectal Cancer management. Don't miss it! From the Jan 2024 DCR CPG - update on Rectal Cancer.

When fifty-something Raphaela Ilgenfritz started feeling tired all the time, she thought her fatigue was tied to menopause.  That led to a serious of doctor visits, which led to a colonoscopy, which led to a diagnosis of rectal cancer, or, as it is more commonly in the United Kingdom, where she lives, bowel cancer.  She had to be outfitted with a colostomy bag, a challenge she immediately embraced.  Raphaela founded Stoma4life, a support group for those with below-the-belt cancers, which grew into a podcast, heard on UKHealthRadio.  This is her story.

In this heartwarming episode, Graham takes the guys on an incredible journey. A true salt-of-the-earth Maritimer and former hockey coach to Taylor, Graham shares the unexpected twists of his battle with rectal cancer. Imagine waking up on July 9, 2021, with a downward pressure in your ass, setting off a series of events that led to a whirlwind of emotions culminating in a cancer diagnosis. Graham regales the hosts with the poignant moments of his experience, from the installation of an ostomy—earning him the endearing title of a "double bagger"—to the transformative cancer treatment that ultimately left him cancer-free. As a baby boomer, Graham's openness about his personal hardships shines through, breaking the mold of traditional stoicism. Join the guys for a candid and uplifting conversation that explores Graham's resilience, vulnerability, and triumph over adversity. Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

In this heartwarming episode, Graham takes the guys on an incredible journey. A true salt-of-the-earth Maritimer and former hockey coach to Taylor, Graham shares the unexpected twists of his battle with rectal cancer. Imagine waking up on July 9, 2021, with a downward pressure in your ass, setting off a series of events that led to a whirlwind of emotions culminating in a cancer diagnosis. Graham regales the hosts with the poignant moments of his experience, from the installation of an ostomy—earning him the endearing title of a "double bagger"—to the transformative cancer treatment that ultimately left him cancer-free. As a baby boomer, Graham's openness about his personal hardships shines through, breaking the mold of traditional stoicism. Join the guys for a candid and uplifting conversation that explores Graham's resilience, vulnerability, and triumph over adversity. Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Dr Kristen K Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Dr J Randolph Hecht from UCLA's David Geffen School of Medicine in Santa Monica, California, discuss the current management and actual cases of relapsed/refractory metastatic colorectal cancer moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/RRmCRC2023)

From MMR/MSI and Neoadjuvant Therapy to "Watch and Wait" and ctDNA, special guests Dr. Al Benson and Dr. Samantha Hendren join the co-hosts for a conversation about the latest NCCN rectal cancer guidelines.     CO-HOSTS Avery Walker, MD, FACS, FASCRS El Paso, TX Avery Walker is dually board-certified in General Surgery and Colorectal Surgery. He earned his medical degree at the University of Illinois in Chicago, his General Surgery residency at Madigan Army Medical Center in Tacoma, Washington, and his Fellowship in Colon and Rectal Surgery at The Ochsner Clinic in New Orleans. A former active-duty officer in the United States Army, Dr. Walker served 13 years as a general and colorectal surgeon with his most recent duty station in El Paso, TX at William Beaumont Army Medical Center. While there he was the Chief of Colon and Rectal surgery as well as the Assistant Program Director for the general surgery residency program. He currently practices colon and rectal surgery at The Hospitals of Providence in El Paso, TX. Dr. Avery Walker is married and has two daughters aged 13 and 9.   Biddy Das, MD, FACS Houston, TX (Twitter @BiddyDas) Dr. Bidhan “Biddy” Das has board certifications for both colon and rectal surgery, and general surgery. His passion for medical education and medical process improvement has resulted in book chapters and publications, and national and regional presentations on those subjects. Highlighting his medical expertise on fecal incontinence, he has been featured on patient education videos and national and international television and radio as a featured expert on these colorectal conditions. Dr Das also has a particular interest in surgeons redefining their careers -- he serves as both a software consultant and private equity consultant in Boston, New York City, and Houston.   Erin King-Mullins, MD, FACS, FASCRS Atlanta, GA (Twitter @eking719) Dr. Erin King-Mullins is a double board-certified general and colorectal surgeon. She graduated summa cum laude from Xavier University of Louisiana. After obtaining her medical degree at Emory University in Atlanta, she completed her internship and residency in general surgery at the Orlando Regional Medical Center in Florida. Her fellowship training in colorectal surgery at Georgia Colon & Rectal Surgical Associates concluded with her joining the practice and serving as Faculty/Research Director for the fellowship program until her transition into private practice with Colorectal Wellness Center. She has a husband with whom she shares an amazing, blended family of 4 daughters. The kids keep them pretty busy, but their favorite times are spent on warm sunny beaches.   Jonathan Abelson, MD, MS Arlington, MA (Twitter @jabelsonmd) Dr. Abelson was born and raised in Scarsdale, New York in the suburbs of New York City.  He has 2 older brothers and both of his parents are dentists.  Dr. Abelson went to college at University Pennsylvania, took 2 years off between college and medical school to work in healthcare consulting.  He then went to medical school at University of Virginia, returned to New York for general surgery residency at Weill Cornell on the upper east side of Manhattan.  Dr. Abelson then did colorectal fellowship at Washington University in St. Louis and am now at Lahey clinic in Burlington, Massachusetts for my first job after training.  He is 2 years into practice and has a wife and two sons. His wife works in wellness consulting and they have a dog named Foster who we adopted in St. Louis.

Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023GE/AudioInterview)

On SurgOnc Today®, J. Joshua Smith, MD, PhD, Glen Balch, MD, and Christina Bailey, MD, discuss modern rectal cancer trials and their relevance to clinical practice.

Is a more curative pathway for metastatic colon cancer patients emerging?  Join Biddy, Jon and Sam as they share cases, perspectives and approaches regarding metastatic colon cancer patients.   CO-HOSTS Biddy Das, MD, FACS Houston, TX (Twitter @BiddyDas) Dr. Bidhan “Biddy” Das has board certifications for both colon and rectal surgery, and general surgery. His passion for medical education and medical process improvement has resulted in book chapters and publications, and national and regional presentations on those subjects. Highlighting his medical expertise on fecal incontinence, he has been featured on patient education videos and national and international television and radio as a featured expert on these colorectal conditions. Dr Das also has a particular interest in surgeons redefining their careers -- he serves as both a software consultant and private equity consultant in Boston, New York City, and Houston.   Jonathan Abelson, MD, MS Arlington, MA (Twitter @jabelsonmd) Dr. Abelson was born and raised in Scarsdale, New York in the suburbs of New York City.  He has 2 older brothers and both of his parents are dentists.  Dr. Abelson went to college at University Pennsylvania, took 2 years off between college and medical school to work in healthcare consulting.  He then went to medical school at University of Virginia, returned to New York for general surgery residency at Weill Cornell on the upper east side of Manhattan.  Dr. Abelson then did colorectal fellowship at Washington University in St. Louis and am now at Lahey clinic in Burlington, Massachusetts for my first job after training.  He is 2 years into practice and has a wife and two sons. His wife works in wellness consulting and they have a dog named Foster who we adopted in St. Louis.   Sam Eisenstein, MD La Jolla, CA  (Twitter @DrE_UCSD) Sam Eisenstein is an Assistant Professor of Colon and rectal surgery and director of Inflammatory Bowel Disease surgery at UC San Diego Health.  He has worked there for the past 8 years after graduating both residency and fellowship at The Mount Sinai Medical Center in New York.  Sam is best known as the founder and organizer of the IBD-NSQIP collaborative, a large multi institutional data collaborative examining outcomes after IBD surgery, but he also is involved in several clinical trials for perianal Crohn's and has extensive experience with stem cell injections for anal fistulae. He is also on the scientific advisory board for the Crohn's and Colitis Foundation for his work on the next big IBD data collaborative, IBD-SIRQC (Surgical Innovation, Research and Quality Collaborative).  Sam has a Wife and 3 kids (6,8, and 3) and spends most of his free time running around after them these days, but also enjoys traveling and getting out into nature with his family.  

This week's episode is part 1 of 5 of a joint mini-series with The Fellow On Call. We will be recapping the current treatment of locally advanced rectal cancer and covering a plenary session abstract from the ASCO 2023 annual meeting,  the PROSPECT Trial. We also cover the concept of non-inferiority trials.

This week's episode will be focusing on the diagnosis and treatment of rectal cancer. We will go over important details on the diagnosis, staging and treatment of both locally advanced and metastatic rectal cancer.

As part of our community health partnership with Valley Health, our conversation this month focused on colon cancer awareness. March is Colorectal Cancer Awareness month. Joining me for the conversation was Dr. Maureen Hill, a fellowship-trained surgical oncologist and board-certified surgeon with Valley Health Surgical Oncology.  We talked about the incidence of colon cancer, who is at risk, and what family history actually means. Dr. Hill explained the types of screening for colorectal cancer and walked us through the process if a test comes back showing the cancer. We discussed how to know which screening option is best for you and talked about the advances that have been made regarding the prep prior to a colonoscopy and she busted a few myths about colostomy bags. She told us about the technology that Valley Health employs for advanced surgical treatments that include: minimally invasive & robot-assisted techniques 2 surgical oncologists (Dr. Hill and Dr. Devin Flaherty) 1 colorectol surgeon (Dr. Maria Sophia VIllanueva) who also treats benign colorectal conditions access to treatment options such as radiation therapy and chemotherapy when indicated multidisciplinary collaboration and team approach to treatment The Valley Health Rectal Cancer Program was the first in our tri-state region to earn accreditation by the National Accreditation Program for Rectal Cancer. Screening colonoscopies are performed at most Valley Health hospitals and the Endoscopy Center at Winchester Medical Center. Learn more about their program: https://www.valleyhealthlink.com/colorectalcancer/ To listen to other conversations in our Community Health series, click here: https://bit.ly/VHhealthpod 

You have a patient who underwent local excision of a rectal cancer. Final pathology demonstrates a T2 lesion. What is the rate of local recurrence? Is excision alone sufficient? Should the patient undergo radical resection or should chemoradiation be offered? Tune in to find out! Join Drs. Peter Marcello, Jonathan Abelson, Tess Aulet and special guest Dr. Jose Guillem MD, MPH, MBA as they discuss high yield papers discussing local excision for Rectal Cancer. You may follow along with the slides mentioned in this episode here: https://behindtheknife.org/video/journal-review-in-colorectal-surgery-local-excision-for-rectal-cancer/ Learning Objectives 1. Describe the features that increase risk of lymph node involvement in early stage rectal cancer 2. Discuss the different options for management of early-stage rectal cancer 3. Describe patient related factors that favor local excision of rectal cancer References: Kidane B, Chadi SA, Kanters S, Colquhoun PH, Ott MC. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum. 2015 Jan;58(1):122-40. doi: 10.1097/DCR.0000000000000293. PMID: 25489704. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, Thomas CR Jr, Chan E, Cataldo PA, Marcet JE, Medich DS, Johnson CS, Oommen SC, Wolff BG, Pigazzi A, McNevin SM, Pons RK, Bleday R. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015 Nov;16(15):1537-1546. doi: 10.1016/S1470-2045(15)00215-6. Epub 2015 Oct 22. PMID: 26474521; PMCID: PMC4984260. Friel CM, Cromwell JW, Marra C, Madoff RD, Rothenberger DA, Garcia-Aguílar J. Salvage radical surgery after failed local excision for early rectal cancer. Dis Colon Rectum. 2002 Jul;45(7):875-9. doi: 10.1007/s10350-004-6320-z. PMID: 12130873. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum. 2002 Feb;45(2):200-6. doi: 10.1007/s10350-004-6147-7. PMID: 11852333. O'Neill CH, Platz J, Moore JS, Callas PW, Cataldo PA. Transanal Endoscopic Microsurgery for Early Rectal Cancer: A Single-Center Experience. Dis Colon Rectum. 2017 Feb;60(2):152-160. doi: 10.1097/DCR.0000000000000764. PMID: 28059911.  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out other colorectal episodes here: https://behindtheknife.org/podcast-category/colorectal/

From "watch and wait" to resection, determining the best approach for high stakes recurrent rectal cancer cases is no easy task. Join Avery, Biddy, Jon, and Sam as they share their personal stories, perspectives and approaches to recurrent rectal cancer.    CO-HOSTS Avery Walker, MD, FACS, FASCRS El Paso, TXAvery Walker is dually board-certified in General Surgery and Colorectal Surgery. He earned his medical degree at the University of Illinois in Chicago, his General Surgery residency at Madigan Army Medical Center in Tacoma, Washington, and his Fellowship in Colon and Rectal Surgery at The Ochsner Clinic in New Orleans. A former active-duty officer in the United States Army, Dr. Walker served 13 years as a general and colorectal surgeon with his most recent duty station in El Paso, TX at William Beaumont Army Medical Center. While there he was the Chief of Colon and Rectal surgery as well as the Assistant Program Director for the general surgery residency program. He currently practices colon and rectal surgery at The Hospitals of Providence in El Paso, TX. Dr. Avery Walker is married and has two daughters aged 13 and 9.   Biddy Das, MD, FACS Houston, TXDr. Bidhan “Biddy” Das has board certifications for both colon and rectal surgery, and general surgery. His passion for medical education and medical process improvement has resulted in book chapters and publications, and national and regional presentations on those subjects. Highlighting his medical expertise on fecal incontinence, he has been featured on patient education videos and national and international television and radio as a featured expert on these colorectal conditions. Dr Das also has a particular interest in surgeons redefining their careers -- he serves as both a software consultant and private equity consultant in Boston, New York City, and Houston.   Jonathan Abelson, MD, MS Arlington, MADr. Abelson was born and raised in Scarsdale, New York in the suburbs of New York City.  He has 2 older brothers and both of his parents are dentists.  Dr. Abelson went to college at University Pennsylvania, took 2 years off between college and medical school to work in healthcare consulting.  He then went to medical school at University of Virginia, returned to New York for general surgery residency at Weill Cornell on the upper east side of Manhattan.  Dr. Abelson then did colorectal fellowship at Washington University in St. Louis and am now at Lahey clinic in Burlington, Massachusetts for my first job after training. He is 2 years into practice and has a wife and two sons. His wife works in wellness consulting and they have a dog named Foster who we adopted in St. Louis.   Sam Eisenstein, MD La Jolla, CA   Sam Eisenstein is an Assistant Professor of Colon and rectal surgery and director of Inflammatory Bowel Disease surgery at UC San Diego Health.  He has worked there for the past 8 years after graduating both residency and fellowship at The Mount Sinai Medical Center in New York.  Sam is best known as the founder and organizer of the IBD-NSQIP collaborative, a large multi institutional data collaborative examining outcomes after IBD surgery, but he also is involved in several clinical trials for perianal Crohn's and has extensive experience with stem cell injections for anal fistulae. He is also on the scientific advisory board for the Crohn's and Colitis Foundation for his work on the next big IBD data collaborative, IBD-SIRQC (Surgical Innovation, Research and Quality Collaborative).  Sam has a Wife and 3 kids (6,8, and 3) and spends most of his free time running around after them these days, but also enjoys traveling and getting out into nature with his family.

On today’s episode, I am speaking with Dr. Lara Lambert. Dr. Lambert is an internal…

Margaret Lang - Survivor of Rectal Cancer   Margaret, is a real estate agent, mother, former high school teacher and now author, she experienced cancer and transformed her life by successfully meeting that challenge. Hopefully chronicling the journey in her book, "Moving Forward: With, Through, and Past Cancer,” will bring faith and hope to many.   www.movingforwardwithmargaret.com   Margaret has been cancer-free for three years.

Our oral board review course includes 92 scenarios that meticulously cover 115 SCORE core topics. Each scenario includes two parts. The first part is a perfectly executed oral board scenario that mimics the real thing. Scenarios are 5 to 7 minutes long and include a variety of tactics and styles. If you are able to achieve this level of performance in your preparation you are sure to pass the oral exam with flying colors. The second part introduces high-yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy-to-understand teaching that covers the most confusing topics we face as general surgeons. We are confident you will find this unique, dual format approach a highly effective way to prepare for the test. Learn more about the Oral Board Review episodes at https://behindtheknife.org/premium/ Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??